Last update 22 Mar 2025

CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)

Overview

Basic Info

Drug Type
CAR-T
Synonyms-
Target
CD19 x CD22
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators), Immunologic cytotoxicity
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
B-Cell Lymphoma
Inactive Indication-
Originator Organization
Beijing Kecellitics Biotech Co., Ltd.
Active Organization
Beijing Kecellitics Biotech Co., Ltd.Hebei Yanda Ludaopei Hospital
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)
NCT05651100
/ Not yet recruitingPhase 1/2
Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma Patients
ChiCTR2000040665
/ RecruitingPhase 1
Donor fully human CD19/CD22 dual target CAR T cells combined with allogeneic hematopoietic stem cell transplantation for the treatment of adult refractory/relapsed B-cell lymphoma. Single-center, open, non-randomized, single-arm clinical trial
100 Clinical Results associated with CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)
Login to view more data
100 Translational Medicine associated with CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)
Login to view more data
100 Patents (Medical) associated with CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)
Login to view more data
100 Deals associated with CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LymphomaPhase 2
China
Beijing Kecellitics Biotech Co., Ltd.
10 Dec 2022
B-Cell LymphomaPhase 2
China
Hebei Yanda Ludaopei Hospital
10 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free